Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

N Of 2: Reflections On The Makena, Avastin Accelerated Approval Withdrawal Hearings

Nov 24 2022

• By Sue Sutter

Makena-reflections — • Source: Shutterstock

Related Content

Genentech Losing Its Legs? <i>Avastin</i> Study Proposal Undercut By Feasibility, Scientific Concerns

Jul 11 2011

Accelerated Approval: US FDA Request For Makena’s Withdrawal Goes Beyond Failed Confirmatory Trial

Oct 06 2020

Genentech, CDER Tussle Over <i>Avastin</i> Hearing Panel And Format

Mar 28 2011

US Accelerated Approval: As Makena Withdrawal Hearing Looms, A Look Back At The Avastin Experience

Jan 19 2022

Makena Accelerated Approval Withdrawal Hearing Should Be In-Person, Covis Tells US FDA

Feb 18 2022

Makena Accelerated Approval Hearing Will Be Virtual, Likely In September Or October

Apr 23 2022

Covis, CDER Lay Out Arguments Ahead Of Makena’s Accelerated Approval Withdrawal Hearing

Oct 07 2022

US FDA Panel Says Covis’ Makena Should Be Withdrawn – And This Time It Wasn’t Close

Oct 19 2022

Makena Hearing Panel Is Deep With Maternal-Fetal Medicine Experience, As Preferred By Covis

Oct 14 2022

Related Companies

Genentech, Inc.

Additional Topics

United States Review Pathway Post Market Regulation & Studies Advisory Committees Regulation Market Access Outlook 2023 Gynecology & Urology BioPharmaceutical

More from Outlook Archive

More from Outlook

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window